NSE - Free Realtime Quote INR

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

1,513.45

+27.70

(+1.86%)

As of 10:19 AM GMT+5:30. Market Open.

30 Most Valuable Drug Companies in 2024

In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]

Insider Monkey 2 months ago

ABBV

NVO

LLY
India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million

The Indian drugmaker, which currently owns about 78.5% stake in Taro, had offered to buy its remaining stake for $38 per share in May. Upon completion of the merger, which is expected to close in the first half of the year, Taro would become a privately held company and will be delisted from the New York Stock Exchange, the companies said. The U.S. government had in November dismissed charges against a former Taro executive who was accused of conspiring to fix generic drug prices between 2013 and 2015.

Reuters 3 months ago

TARO

SUNPHARMA.NS
+1.86%
Top 20 Most Valuable Indian Companies

In this article, we will look into the top 20 most valuable Indian companies. If you want to skip our detailed analysis, you can go directly to the Top 5 Most Valuable Indian Companies. An Outlook of the Indian Economy According to Deloitte’s Indian Economic Outlook 2023, The Indian economy is poised to emerge as […]

Insider Monkey 5 months ago

HDB

RELIANCE.NS

TCS.NS
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern

GlobeNewswire 6 months ago

SUNPHARMA.BO

SUNPHARMA.NS
+1.86%
PHIL.MI
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States. The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24. U.S.-based drugmakers Mallinckrodt and Viatris , UK-based Hikma Pharmaceuticals and Indian drugmaker Sun Pharmaceutical Industries confirmed on Thursday they began shipping their generic versions of the drug, which is also approved for a binge-eating disorder in adults.

Reuters 7 months ago

TAK

MNKTQ

SUNPHARMA.NS
+1.86%
UPDATE 1-US FDA halts India's Sun Pharma trials on dermatological drug

The U.S. Food and Drug Administration (FDA) has asked India's Sun Pharmaceutical Industries Ltd to halt tests on one dose of an experimental dermatological drug due to the potential of blood clots, the company said on Tuesday. The FDA has also said that patients with alopecia areata - an autoimmune condition that results in patchy hair loss - on the 12 mg dose of the drug deuruxolitinib should discontinue its use, Sun Pharma said. However, there were no thrombotic events, or blood clot formations, in patients taking the 8 mg dose and the FDA has not placed those trials on hold, Sun Pharma said.

Reuters 11 months ago

SUNPHARMA.NS
+1.86%

Performance Overview

Return	SUNPHARMA.NS	S&P BSE SENSEX
YTD	+20.85%	+2.34%
1-Year	+56.00%	+23.10%
3-Year	+144.57%	+54.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

30 Most Valuable Drug Companies in 2024

India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million

Top 20 Most Valuable Indian Companies

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

UPDATE 1-US FDA halts India's Sun Pharma trials on dermatological drug

Performance Overview